What to Expect

In clinical efficacy studies of up to 2 years duration, 2,629 subjects completed 33,160 cycles of use without any other contraception. Pregnancy rates in the clinical trials were less than one per 100 woman-years of use.

Select Safety Information

Stop Syeda® if an arterial thrombotic event or venous thromboembolic (VTE) event occurs. Stop Syeda if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately. Syeda® is contraindicated in females over 35 years old who smoke. Advise the nursing mother to use other forms of contraception, when possible, until she has weaned her child. COCs can reduce milk production in breastfeeding mothers. This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases. Progestin drospirenone may increase potassium. Therefore, you should not take Syeda if you have kidney, liver or adrenal disease because this could cause serious heart and health problems. Please click here for the complete boxed warning & for more Important Risk Information.

Please click here for full Prescribing Information and Patient Information.